Skip to main content

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Publication ,  Journal Article
Bigner, DD; Brown, MT; Friedman, AH; Coleman, RE; Akabani, G; Friedman, HS; Thorstad, WL; McLendon, RE; Bigner, SH; Zhao, XG; Pegram, CN ...
Published in: J Clin Oncol
June 1998

PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment. METHODS: In this phase I trial, eligible patients were treated with a single injection of 131I-labeled 81C6. Cohorts of three to six patients were treated with escalating dosages of 131I (starting dose of 20 mCi with a 20-mCi escalation in subsequent cohorts) administered through an Ommaya reservoir in the SCRC. Patients were followed up for toxicity and response until death or for a minimum of 1 year after treatment. The SCRC patients, who were previously irradiated, were followed up without additional treatment unless progressive disease was identified. RESULTS: We administered 36 treatments of 131I doses up to 120 mCi to 34 previously irradiated patients with recurrent or metastatic brain tumors. Dose-limiting toxicity was reached at 120 mCi and was limited to neurologic or hematologic toxicity. None of the patients treated with less than 120 mCi developed significant neurologic toxicity; one patient developed major hematologic toxicity (MHT). The estimated median survival for patients with glioblastoma multiforme (GBM) and for all patients was 56 and 60 weeks, respectively. CONCLUSION: The MTD for administration of 131I-labeled 81C6 into the SCRCs of previously irradiated patients with recurrent primary or metastatic brain tumors was 100 mCi. The dose-limiting toxicity was neurologic toxicity. We are encouraged by the minimal toxicity and survival in this phase I trial. Radiolabeled mAbs may improve the current therapy for brain tumor patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 1998

Volume

16

Issue

6

Start / End Page

2202 / 2212

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tomography, Emission-Computed
  • Tenascin
  • Survival Rate
  • Oncology & Carcinogenesis
  • Nervous System Diseases
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., … Zalutsky, M. R. (1998). Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol, 16(6), 2202–2212. https://doi.org/10.1200/JCO.1998.16.6.2202
Bigner, D. D., M. T. Brown, A. H. Friedman, R. E. Coleman, G. Akabani, H. S. Friedman, W. L. Thorstad, et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.J Clin Oncol 16, no. 6 (June 1998): 2202–12. https://doi.org/10.1200/JCO.1998.16.6.2202.
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun;16(6):2202–12.
Bigner, D. D., et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.J Clin Oncol, vol. 16, no. 6, June 1998, pp. 2202–12. Pubmed, doi:10.1200/JCO.1998.16.6.2202.
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun;16(6):2202–2212.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 1998

Volume

16

Issue

6

Start / End Page

2202 / 2212

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tomography, Emission-Computed
  • Tenascin
  • Survival Rate
  • Oncology & Carcinogenesis
  • Nervous System Diseases
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging